May 12, 2021 -- VBI Vaccines' prophylactic 3-antigen hepatitis B vaccine candidate offers better protection from the disease than the mono-antigenic vaccine Engerix-B, according to phase III study results.
VBI's vaccine offers higher seroprotection rates and five to eight times higher antibody geometric mean concentration regardless of body mass index, diabetes status, and age. No safety issues were observed.
The vaccine is composed of the spike, pre-S1, and pre-S2 surface antigens of the hepatitis B virus and is approved for use and commercially available in Israel. The company has previously filed regulatory submissions for the vaccine candidate in the U.S. and Europe in November 2020 and is in the process of filing submissions for Canada and the U.K.
Approximately 1,600 adults participated in the study, which was published in the Lancet Infectious Diseases.